Granules India informs about updates

05 Nov 2025 Evaluate
Granules India has informed that the US FDA has issued an Establishment Inspection Report (EIR) to Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA, for the Pre-Approval Inspection (PAI) conducted by it in June 2025 for a first-to-file controlled substance ANDA. There was one observation during the inspection, and it has been resolved. 

The above information is a part of company’s filings submitted to BSE.  

Granules India Share Price

567.85 -6.10 (-1.06%)
20-Jan-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1641.45
Dr. Reddys Lab 1191.65
Cipla 1381.10
Zydus Lifesciences 879.35
Lupin 2169.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×